VANCOUVER, British Columbia--(BUSINESS WIRE)--Response Biomedical Corporation (TSX:RBM) (OTCBB:RPBIF) reported that clinical products revenue for the three and six month periods ended June 30, 2009 increased 373% and 208% to $1,805,308 and $3,548,014, respectively, compared to $381,615 and $1,150,760 for the same periods in 2008. Total revenues for the second quarter increased 174% from the same quarter in 2008, from $997,515 in Q2/2008 to $2,735,415 in Q2/2009.
